U-Ploid Presents First Lyvanta™ Data Demonstrating Reduction of Aneuploidy in Aged Oocytes at ASRM 2025

San Antonio, Texas — October 27, 2025 U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.

Meiotic aneuploidy remains the leading cause of infertility and miscarriage, arising in more than 50% of eggs in women over 33. Oocytes frequently experience age-related errors that cause an incorrect number of chromosome copies to be transferred to the embryo. Lyvanta™ targets this mechanism directly, offering a first-in-class therapeutic approach to reduce age-related errors and improve egg quality.

“Presenting our first Lyvanta™ data at ASRM marks a major milestone for U-Ploid,” said Dr Jordan Abdi, Co-Founder and CEO. “These findings represent a significant step towards translating our work into clinical applications that could improve fertility outcomes for women of advanced maternal age.”

In a preclinical mouse model, Lyvanta™ treatment achieved an 84.3% reduction in premature separation of sister chromatids (PSSC) compared with untreated aged oocytes (p = 0.002), restoring error rates to levels observed in young controls. The proportion of error-free oocytes increased by nearly 20 percentage points, demonstrating a robust rescue of meiotic fidelity.

“Our data provide clear proof-of-concept that pharmacologic intervention can reduce age-related meiotic errors,” added Dr Alexandre Webster, Co-Founder and CSO. “We are excited to discuss these results with the reproductive medicine community.”

The ASRM presentation is being delivered by U-Ploid’s scientific team, including Dr Alex Webster, Dr Eirini Bellou, Professor Alison Campbell (Care Fertility), and Dr Chloe Charalambous.

References cited in the ASRM 2025 abstract

1. Gruhn JR et al. (2019). Chromosome errors in human eggs shape natural fertility over reproductive life span.Science. PMID: 31604276
2. Herbert M et al. (2015). Meiosis and maternal aging: insights from aneuploid oocytes and trisomy births. Cold Spring Harb Perspect Biol. PMID: 25833844
3. Charalambous C et al. (2023). Aneuploidy in mammalian oocytes and the impact of maternal ageing. Nat Rev Mol Cell Biol. PMID: 36068367

About ASRM

The American Society for Reproductive Medicine (ASRM) Annual Meeting is the leading global forum for advances in reproductive science and medicine, bringing together clinicians, researchers, and innovators to share breakthroughs in fertility and reproductive health.

Learn more at https://www.asrm.org/

‍